Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications.
Progressive p16 methylation has been associated with metastasis and invasive phenotypes in many cancers. Loss of E-cadherin (CDH1) function contributes to breast cancer progression by promoting cell proliferation, invasion and metastasis. Using methylation-specific PCR, aberrant hypermethylation of p16 and CDH1 in tumor and plasma was analyzed and correlated with levels of serum protein markers, carcinoembryonic antigen (CEA) and carcinoma antigen 15-3 (CA15.3), in 36 patients with invasive ductal breast cancer. Aberrant p16 methylation was found in 11% (4/36) of primary tumors and 8% (3/36) of plasma samples. Aberrant CDH1 methylation was detected in 25% (9/36) of primary tumors and 20% (7/36) of plasma samples. p16 and/or CDH1 hypermethylation was found in 31% (11/36) of primary breast carcinomas and 82% (9/11) of breast cancer patients with tumoral methylation showing identical epigenetic changes in plasma. The 25 patients without tumoral methylation did not show epigenetic changes in the plasma. Tumoral p16 methylation was significantly associated with advanced tumor stage (p=0.028; Fisher's exact test), tumor size (p=0.017) and nodal metastasis (p=0.002). However, p16 methylation in plasma was only associated with nodal metastasis (p=0.012). Altogether, aberrant p16 methylation in plasma and elevated serum CEA level were associated with advanced tumor stage (p=0.033), tumor size (p=0.022) and extensive nodal metastasis (p=0.003). With clinical implications, p16 hypermethylation in plasma and/or raised serum CEA levels may prove useful as diagnostic and prognostic markers for breast cancer.
Hu
Xi-Chun
XC
Department of Surgery, University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, PR China.
Wong
Ivy H N
IH
Chow
Louis W C
LW
D000328:Adult; D000368:Aged; D017209:Apoptosis; D001943:Breast Neoplasms / Q000235:genetics*; D015820:Cadherins / Q000096:biosynthesis; D002272:Carcinoembryonic Antigen / Q000096:biosynthesis; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000473:pathology; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000096:biosynthesis; D004247:DNA / Q000235:genetics; D019175:DNA Methylation; D018450:Disease Progression; D005260:Female; D019942:Genes, p16; D006801:Humans; D008207:Lymphatic Metastasis; D008745:Methylation; D008875:Middle Aged; D018396:Mucin-1 / Q000096:biosynthesis; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D010641:Phenotype; D016133:Polymerase Chain Reaction; D011379:Prognosis; D013447:Sulfites
D015820:Cadherins; D002272:Carcinoembryonic Antigen; D019941:Cyclin-Dependent Kinase Inhibitor p16; D018396:Mucin-1; D013447:Sulfites; D004247:DNA